blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2056832

EP2056832 - COMPOSITIONS, SUITABLE FOR ORAL ADMINISTRATION, COMPRISING A TRIAZOLO [4, 5-D]PYRIMIDIN DERIVATE [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  01.03.2022
Database last updated on 16.11.2024
FormerThe patent has been granted
Status updated on  17.02.2017
FormerGrant of patent is intended
Status updated on  23.11.2016
Most recent event   Tooltip04.03.2022Revocation of patentpublished on 06.04.2022  [2022/14]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2017/12]
Former [2009/20]For all designated states
AstraZeneca AB
151 85 Södertälje / SE
Inventor(s)01 / BANKS, Simon
AstraZeneca R & D Charnwood
Bakewell Road
Loughborough Leicestershire LE11 5RH / GB
 [2017/12]
Former [2009/20]01 / BANKS, Simon
AstraZeneca R & D Charnwood Bakewell Road
Loughborough Leicestershire LE11 5RH / GB
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2017/12]Berry, Ian Gordon
AstraZeneca
Global Intellectual Property
Patents
Mereside - Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
Application number, filing date07794121.920.08.2007
[2009/20]
WO2007SE00736
Priority number, dateUS20060823083P21.08.2006         Original published format: US 823083 P
[2009/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008024045
Date:28.02.2008
Language:EN
[2008/09]
Type: A1 Application with search report 
No.:EP2056832
Date:13.05.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 28.02.2008 takes the place of the publication of the European patent application.
[2009/20]
Type: B1 Patent specification 
No.:EP2056832
Date:22.03.2017
Language:EN
[2017/12]
Search report(s)International search report - published on:SE28.02.2008
(Supplementary) European search report - dispatched on:EP27.11.2012
ClassificationIPC:A61K31/519, A61K9/20, A61K9/48
[2009/20]
CPC:
A61K9/2009 (EP,NO,US); A61K31/519 (EP,KR,NO,US); A61K47/38 (KR,NO,US);
A61K47/02 (NO,US); A61K47/10 (NO,US); A61K47/36 (NO,US);
A61K9/16 (KR); A61K9/2018 (EP,NO,US); A61P37/02 (EP);
A61P43/00 (EP); A61P7/00 (EP); A61P7/02 (EP);
A61P9/00 (EP); A61P9/10 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/12]
Former [2009/20]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL23.03.2009
BA23.03.2009
HR23.03.2009
MK23.03.2009
RS23.03.2009
TitleGerman:ZUSAMMENSETZUNGEN ZUR ORALEN VERABREICHUNG MIT EINEM TRIAZOLO [4, 5-D]PYRIMIDIN-DERIVAT[2009/20]
English:COMPOSITIONS, SUITABLE FOR ORAL ADMINISTRATION, COMPRISING A TRIAZOLO [4, 5-D]PYRIMIDIN DERIVATE[2009/20]
French:COMPOSITIONS POUR ADMINISTRATION ORALE COMPRENANT UN DÉRIVÉ DE TRIAZOLO [4, 5]PYRIMIDINE[2009/20]
Entry into regional phase23.03.2009National basic fee paid 
23.03.2009Search fee paid 
23.03.2009Designation fee(s) paid 
23.03.2009Examination fee paid 
Examination procedure23.03.2009Examination requested  [2009/20]
07.06.2013Amendment by applicant (claims and/or description)
21.05.2014Despatch of a communication from the examining division (Time limit: M06)
28.11.2014Reply to a communication from the examining division
24.11.2016Communication of intention to grant the patent
08.02.2017Fee for grant paid
08.02.2017Fee for publishing/printing paid
08.02.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.05.2014
Opposition(s)Opponent(s)01  18.12.2017  21.12.2017  ADMISSIBLE
Wittkopp, Alexander
Bogenallee 5
20144 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 02  21.12.2017  05.01.2018  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Herzberg, Kristina
Hexal AG
Industriestraße 25
DE-83607 Holzkirchen / DE
 03  22.12.2017  05.01.2018  ADMISSIBLE
Generics [UK] Limited (trading as Mylan)
Building 4
Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
 [2021/35]
Former [2021/10]
Opponent(s)01  18.12.2017  21.12.2017  ADMISSIBLE
Wittkopp, Alexander
Bogenallee 5
20144 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 02  21.12.2017  05.01.2018  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Herzberg, Kristina
Hexal AG
Industriestraße 25
DE-83607 Holzkirchen / DE
 03  22.12.2017  05.01.2018  ADMISSIBLE
Generics [UK] Limited (trading as Mylan)
Building 4
Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Gill Jennings & Every LLP
APC The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
Former [2019/33]
Opponent(s)01  18.12.2017  21.12.2017  ADMISSIBLE
Wittkopp, Alexander
Bogenallee 5
20144 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 02  21.12.2017  05.01.2018  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Guggenberger, Christoph
Hexal AG
Industriestraße 25
83607 Holzkirchen / DE
 03  22.12.2017  05.01.2018  ADMISSIBLE
Generics [UK] Limited (trading as Mylan)
Building 4
Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Gill Jennings & Every LLP
APC The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
Former [2018/50]
Opponent(s)01  18.12.2017  21.12.2017  ADMISSIBLE
Wittkopp, Alexander
Bogenallee 5
20144 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 02  21.12.2017  05.01.2018  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Haseltine Lake LLP
Bürkleinstrasse 10
80538 München / DE
 03  22.12.2017  05.01.2018  ADMISSIBLE
Generics [UK] Limited (trading as Mylan)
Building 4
Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Gill Jennings & Every LLP
APC The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
Former [2018/11]
Opponent(s)01  18.12.2017  21.12.2017  ADMISSIBLE
Wittkopp, Alexander
Bogenallee 5
20144 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 02  21.12.2017  05.01.2018  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Basra, Sandeep
Haseltine Lake LLP
Bürkleinstrasse 10
80538 München / DE
 03  22.12.2017  05.01.2018  ADMISSIBLE
Generics [UK] Limited (trading as Mylan)
Building 4
Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Gill Jennings & Every LLP
APC The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
Former [2018/06]
Opponent(s)01  18.12.2017  21.12.2017  ADMISSIBLE
Wittkopp, Alexander
Bogenallee 5
20144 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 02  21.12.2017   
Hexal Biotech GmbH
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Basra, Sandeep
Haseltine Lake LLP
Bürkleinstrasse 10
80538 München / DE
 03  22.12.2017    ADMISSIBLE
Generics [UK] Limited (trading as Mylan)
Building 4
Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Gill Jennings & Every LLP
APC The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
Former [2018/05]
Opponent(s)01  18.12.2017  21.12.2017  ADMISSIBLE
Wittkopp, Alexander
Bogenallee 5
20144 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 02  21.12.2017   
Hexal Biotech GmbH
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Basra, Sandeep
Haseltine Lake LLP
Bürkleinstrasse 10
80538 München / DE
Former [2018/04]
Opponent(s)01  18.12.2017  21.12.2017  ADMISSIBLE
Wittkopp, Alexander
Bogenallee 5
20144 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
deletedDeletion: Legal effect of rejection of opposition [ N /P ]
16.01.2018Invitation to proprietor to file observations on the notice of opposition
24.05.2018Reply of patent proprietor to notice(s) of opposition
11.04.2019Date of oral proceedings
22.05.2019Despatch of minutes of oral proceedings
22.05.2019Date of despatch of rejection of opposition
23.08.2021Legal effect of revocation of patent [2022/14]
17.12.2021Despatch of communication that the patent will be revoked
Appeal following opposition09.07.2019Appeal received No.  T2049/19
01.10.2019Statement of grounds filed
23.08.2021Result of appeal procedure: revocation of the patent
17.12.2021Despatch of the decision of the Board of Appeal
22.07.2019Appeal received No.  T2049/19
30.09.2019Statement of grounds filed
23.08.2021Result of appeal procedure: revocation of the patent
17.12.2021Despatch of the decision of the Board of Appeal
22.07.2019Appeal received No.  T2049/19
23.08.2021Result of appeal procedure: revocation of the patent
17.12.2021Despatch of the decision of the Board of Appeal
23.08.2021Date of oral proceedings
Fees paidRenewal fee
31.08.2009Renewal fee patent year 03
31.08.2010Renewal fee patent year 04
31.08.2011Renewal fee patent year 05
31.08.2012Renewal fee patent year 06
02.09.2013Renewal fee patent year 07
01.09.2014Renewal fee patent year 08
31.08.2015Renewal fee patent year 09
31.08.2016Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipMC22.03.2017
[2018/18]
Documents cited:Search[A]WO0136421  (ASTRAZENECA AB [SE], et al) [A] 1-15* the whole document *;
 [A]WO2005113006  (BOEHRINGER INGELHEIM INT [DE], et al) [A] 1-15 * the whole document *
International search[X]WO0034283  (ASTRAZENECA UK LTD [GB], et al);
 [X]WO0192262  (ASTRAZENECA AB [SE], et al);
 [A]US2004001885  (KOSITPRAPA UNCHALEE [US], et al);
 [A]WO2004024127  (PHARMACIA ITALIA SPA [IT], et al);
 [A]WO2004037263  (RANBAXY LAB LTD [IN], et al);
 [A]WO2004052342  (ASTRAZENECA AB [SE], et al)
OppositionWO0192262
 WO2004032905
 WO2004037263
 WO2004096215
 WO2006072878
 WO0034283
 WO0136421
 US2004001885
 WO2004024127
 WO2004052342
 WO2005113006
 WO2008024045
    - J. Sirca, S. Srcic, B. Kofler, "Formulation and Process Development of Extrusion/Spheronization Pellets", Farmacevtski Vestnik, (19970900), vol. 48, pages 310 - 311, XP055447259
    - Raymond C Rowe et al, Handbook of Pharmaceutical Excipients. 5th ed., Pharmaceutical Press, (20060000), pages 96-99,132-135,211-213,336-343,385 - 398,430-433,449-453,611-616,701-704, XP055449308
    - GILBERT S. BANKER et al., Modern Pharmaceutics. 4th ed, rev. and exp., Marcel Dekker, (20020000), pages 296 - 297,301, XP055369684
    - "Chaptet 32,38,45,57", Alfonso R. Gennaro, Remington, The Science and Practice of Pharmacy. 20th ed., (20000000), pages 654-658,713-714, 858 - 863,884-885,1114-1115, XP055449338
    - "Tablets", ALLEN et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 8th ed., (20050000), pages 233 - 238 , 253-254, XP055449342
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.